English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background and Hypothesis: Oxaliplatin (OXL)-associated Chemotherapyinduced Peripheral Neuropathy (CIPN) is a frequent, potentially severe, and dose-limiting toxicity of colorectal cancer treatment. CIPN can persist for years beyond chemotherapy completion, causing significant challenges for cancer survivors due to its negative influence on quality of life. This work builds upon preliminary observations that platinum drugs lead to the release of a damageassociated protein, high mobility group box-1 (HMGB1). Drug-induced release of this protein from the nucleus into the cytosol and eventually into the extracellular compartment can sensitize primary afferent sensory neurons for prolonged periods of time, eliciting CIPN pain behavior in rodents. Inhibition of HMGB1 nuclear translocation through administration of olaparib may serve to diminish CIPN pain in a rodent model.

Control of Chemotherapy-Induced Peripheral Neuropathy and HMGB1 Cytosolic Translocation in Dorsal Root Ganglion Sensory Neurons Using Olaparib